

REMARKS

Claims 1-4, 6-8, 11, 14, 17-19, and 21-27 are currently pending. Claims 7, 11, 19, 21-23, 25, and 26 are currently withdrawn from consideration. Applicants wish to thank the Office for indicating that claims 1-4, 6, 8, 24, and 27 are allowed.

By way of this Amendment, claims 2, 6, 7, 17, and 18 have been amended, no claims have been newly added, and claims 11, 14, 19, 21-23, 25, and 26 have been canceled. No new matter has been added.

Claims 2 and 6 have been amended to correct typographical-type errors in the claims. All composition claims have previously been indicated as allowed, and Applicants assert that the composition claims remain allowable.

Claims 17 and 18 have been amended to rewrite the method claims according to the preference of the Examiner as stated in the Office Action. All other method claims have been canceled. Rejoinder of the method claims is requested.


Process claim 7 has been amended to more clearly demonstrate that all substituents are defined in (depend from) claim 1. Rejoinder of the process claim is requested.

Conclusion

Applicants assert that the instant Amendment places the application in a condition for allowance, and such allowance is respectfully requested.

The Examiner is invited to contact the undersigned at (919) 483-8160, to discuss this case, if desired.

Respectfully submitted,



J. Scott Young
Attorney for Applicants
Reg. No. 45,582

Date: April 9 2008
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709
(919) 483-8160
fax: (919) 483-7988
Scott.S.Young@GSK.com